Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

This study should estimate the dose proportionality of BAY94-8862 IR tablets.

Phase 1

Bayer